BioMarin Pharmaceutical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioMarin Pharmaceutical Inc.
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to investigational products from Roche and CSL Behring/UniQure.
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted.
- Other Names / Subsidiaries
- Huxley Pharmaceuticals, Inc.
- LEAD Therapeutics, Inc.
- Prosensa Holding N.V
- Zacharon Pharmaceuticals, Inc.
- ZyStor Therapeutics, Inc.